Schedule a Call Back
Trump’s pharma orders may hit Indian exports
Industry News- May 08,25
Trump's policy push aims to boost domestic production, grant faster approvals to U.S.-based facilities, conduct stricter inspections of foreign plants, and impose higher compliance fees on overseas manufacturers.
A recent report by Nuvama Research warns that new executive orders issued by U S President Donald Trump could pose major challenges for Indian pharmaceutical exporters, particularly those serving the U.S. generic drug market. The orders prioritise reshoring of drug manufacturing, including Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and other raw materials, to the United States—posing a direct threat to India’s cost-driven pharma model.
India, long recognised as the 'pharmacy of the world', has built a strong global presence in the generic drug space due to its low-cost manufacturing advantage. However, Trump's policy push aims to boost domestic production, grant faster approvals to U.S.-based facilities, conduct stricter inspections of foreign plants, and impose higher compliance fees on overseas manufacturers.
The report highlights that these measures could undermine India’s cost competitiveness and reshape the U.S. generic supply chain. Another looming concern is a possible mandate to disclose API sources, which could expose Indian pharma firms’ dependence on Chinese imports, making them vulnerable to increased scrutiny.
Additionally, one of the executive orders limits funding for research involving enhanced virus pathogenicity, underscoring a broader U.S. biosecurity agenda. If fully implemented, the new policies could significantly disrupt global pharmaceutical supply chains, eroding India's export position and increasing pressure on Indian drugmakers to adapt to stricter U S regulations.
(ANI)
Related Stories
Electrical & Electronics
Will solar manufacturing glow in India as renewable energy demand surges?
While India has successfully increased domestic solar module production, import of solar cells remains high. As India plans to add 60-65 GW of solar capacity, will it be a sunshine moment for solar ..
Read moreProcess Equipment
Vipul Organics forays into membrane manufacturing
The company will build a separate facility for membrane manufacturing at its greenfield project at Saykha, Gujarat.
Read morePolicy Regulation
We see 40-50% growth in all our key businesses: Ram Iyer
In this interaction, Ram Iyer, Founder and CEO, Vayana, elaborates on challenges faced by MSMEs in accessing finance and probable solutions to ease their situation.
Read moreRelated Products
Programmable Controllers - Pcd-33a Series
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Pro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.
Gasket Graphite Powder
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Arihant Packing & Gasket Company offers a wide range of gasket graphite powder.
Asahi Kasei expands 3D printing filament sales in North America
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more
latest News
Subscribe to iNoW
For Industry News on WhatsApp, Give a Miss Call on: +91 84228 74016
